Heptares secures £21 million in Series A fund raising
Funds to accelerate development of pipeline of small molecules against high-value GPCR drug targets
25-Feb-2009 -
Heptares Therapeutics Ltd announced it has raised £21 million (US$30 million) of equity finance in a successful Series A private round from three blue-chip international venture capital firms. Clarus Ventures led the syndicate, which includes the founding investor, MVM Life Science Partners, and ...
diseases
Life Sciences
membrane proteins
+2